Diphtheria-tetanus-pertussis vaccine: past, current & future
- PMID: 34856810
- DOI: 10.2217/fmb-2021-0167
Diphtheria-tetanus-pertussis vaccine: past, current & future
Abstract
The diphtheria-tetanus-pertussis (DTP) vaccine can prevent diphtheria, tetanus and pertussis. The component antigens of the DTP vaccine had long been monovalent vaccines. The pertussis vaccine was licensed in 1914. The same year, the mixtures of diphtheria toxin and antitoxin were put into use. In 1926, alum-precipitated diphtheria toxoid was registered, and in 1937 adsorbed tetanus toxoid was put on the market. The development of numerous effective DTP vaccines quickly stimulated efforts to combine DTP with other routine vaccines for infants. This overview covers the most important information regarding the invention of DTP vaccines, their modifications and the needs that should be focused on in the future.
Keywords: DTP vaccine; acellular pertussis vaccine; animal and human trials; diphtheria; experimental vaccine; pertussis; prevention; tetanus; waning immunity; whole-cell pertussis vaccine.
Similar articles
-
A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.N Engl J Med. 1996 Feb 8;334(6):341-8. doi: 10.1056/NEJM199602083340601. N Engl J Med. 1996. PMID: 8538704 Clinical Trial.
-
Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2006 Mar 24;55(RR-3):1-34. MMWR Recomm Rep. 2006. PMID: 16557217
-
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000. Drugs. 2012. PMID: 22931522 Review.
-
Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age.Pediatr Infect Dis J. 1993 Aug;12(8):638-43. doi: 10.1097/00006454-199308000-00003. Pediatr Infect Dis J. 1993. PMID: 8414775 Clinical Trial.
-
Waning Immunity After Receipt of Pertussis, Diphtheria, Tetanus, and Polio-Related Vaccines: A Systematic Review and Meta-analysis.J Infect Dis. 2022 Feb 15;225(4):557-566. doi: 10.1093/infdis/jiab480. J Infect Dis. 2022. PMID: 34543411
Cited by
-
Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines.Toxins (Basel). 2023 Sep 8;15(9):563. doi: 10.3390/toxins15090563. Toxins (Basel). 2023. PMID: 37755989 Free PMC article. Review.
-
Tetanus-diphtheria vaccine can prime SARS-CoV-2 cross-reactive T cells.Front Immunol. 2024 Jul 18;15:1425374. doi: 10.3389/fimmu.2024.1425374. eCollection 2024. Front Immunol. 2024. PMID: 39091504 Free PMC article.
-
Global analysis of tetanus incidence and mortality in children under 5 years: findings from the Global Burden of Disease Study 2021.BMJ Paediatr Open. 2025 May 14;9(1):e003326. doi: 10.1136/bmjpo-2025-003326. BMJ Paediatr Open. 2025. PMID: 40374285 Free PMC article.
-
Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines.Front Immunol. 2024 Aug 14;15:1438030. doi: 10.3389/fimmu.2024.1438030. eCollection 2024. Front Immunol. 2024. PMID: 39206192 Free PMC article. Review.
-
Bioinformatic development of a recombinant trivalent synthetic protein construct using PTXa, Tox, and TetX toxins as a DTP vaccine candidate.Arch Razi Inst. 2024 Aug 1;79(4):777-788. doi: 10.32592/ARI.2024.79.4.777. eCollection 2024 Aug. Arch Razi Inst. 2024. PMID: 40256581 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous